



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bucala et al.

Serial No.: 08/243,342

Group Art Unit: To Be Assigned

Filed: May 16, 1994

Examiner: To Be Assigned

For: INHIBITION OF MIGRATION INHIBITORY
FACTOR IN THE TREATMENT OF
DISEASES INVOLVING
CYTOKINE-MEDIATED TOXICITY

Attorney Docket No.: 7815-008

RECEIVED

AUG 16 1994

APPLICATION DIVISION TRANSMITTAL IN RESPONSE TO NOTICE TO FILE MISSING PARTS

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

In response to the Notice to File Missing Parts of an Application under 37 C.F.R. §1.53(d) issued on June 30, 1994, in connection with the above-identified application, Applicants submit herewith: a response to comply with the sequence rules, a paper copy of the "Sequence Listing", a computer readable form copy of the "Sequence Listing" and a Preliminary Amendment.

The fee required to be filed with the accompanying Declaration under 37 C.F.R. §1.16(e) has been estimated to be \$130.00. Please charge the required fee to Pennie & Edmonds Deposit Account No. 16-1150. A duplicate copy of this sheet is enclosed. Applicants respectfully request that the foregoing documents be entered into the file of the above-identified application.

EXPRESS MAIL CERTIFICATION

"Express Mail" label No. TB 668654591 US

Date of Deposit

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231

Alvin Foster

(Type or print name of person mailing paper or fee)

(Signature of person mailing paper or fee)

PENY-291109.1

Respectfully submitted,

Date July 28, 1994

Laura A. Coruzzi / by Victor K. Lee
Laura A. Coruzzi Reg. No. 35,750
30,742
(Reg. No.)

PENNIE & EDMONDS
1155 Avenue of the Americas
New York, New York 10036-2711

(212) 790-9090



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3

Application of: BUCALA et al.

Serial No.: 08/243,342

Group Art Unit: To Be Assigned

Filed: May 16, 1994

Examiner: To Be Assigned

For: INHIBITION OF MIGRATION
INHIBITORY FACTOR IN THE
TREATMENT OF DISEASES
INVOLVING CYTOKINE-
MEDIATED TOXICITY

Attorney Docket No.: 7815-008

RESPONSE TO NOTICE TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

Pursuant to a Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated June 30, 1994 in connection with the above-identified application, Applicants submit herewith Sequence Listings in paper and computer readable form pursuant to 37 C.F.R. §1.821(c) and (e), respectively.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(g), herein does not include new matter.

EXPRESS MAIL CERTIFICATION

"Express Mail" label No. TB 668654591 US Date of Deposit July 28, 1994
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Advin Foster
(Type or print name of person mailing paper or fee)
(Signature of person mailing paper or fee)

PENY-285085.1

The time for response to the Notice to Comply has been set for July 30,

1994.

Respectfully submitted,

Date July 28, 1994

Laura A. Coruzzi / by Victor H. Lee
Laura A. Coruzzi Reg. No. 35,750
30,742
(Reg. No.)

PENNIE & EDMONDS
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

☐ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☐ 7.

Other: _____

Applicant must provide:

☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☐ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
--------------------	-------------	-----------------------	------------------------

08/243,342 05/16/94 BUCALA R 7015-002

0381/0600

PENNIE & EDMONDS
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 10036-2711

0000

DATE MAILED: 06/30/94

RECEIVED

AUG 16 1994

APPLICATION DIVISION

NOTICE TO FILE MISSING PARTS OF APPLICATION FILING DATE GRANTED

An Application Number and Filing Date have been assigned to this application. However, the items indicated below are missing. The required items and fees identified below must be timely submitted **ALONG WITH THE PAYMENT OF A SURCHARGE** for items 1 and 3-6 only of \$_____ for large entities or \$_____ for small entities who have filed a verified statement claiming such status. The surcharge is set forth in 37 CFR 1.16(e).

If all required items on this form are filed within the period set below, the total amount owed by applicant as a ☐ large entity, ☐ small entity (verified statement filed), is \$_____.

Applicant is given **ONE MONTH FROM THE DATE OF THIS LETTER, OR TWO MONTHS FROM THE FILING DATE** of this application, **WHICHEVER IS LATER**, within which to file all required items and pay any fees required above to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

1. ☐ The statutory basic filing fee is: ☐ missing ☐ insufficient. Applicant as a ☐ large entity ☐ small entity, must submit \$_____ to complete the basic filing fee.
2. ☐ Additional claim fees of \$_____ as a ☐ large entity, ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
3. ☐ The oath or declaration:
☐ is missing.
☐ does not cover items omitted at time of execution.
4. ☐ An oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date is required.
5. ☐ The oath or declaration does not identify the application to which it applies. An oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
6. ☐ The signature to the oath or declaration is: ☐ missing; ☐ a reproduction; ☐ by a person other than the inventor or a person qualified under 37 CFR 1.42, 1.43, or 1.47. A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
7. ☐ The signature of the following joint inventor(s) is missing from the oath or declaration:
_____. An oath or declaration listing the names of all inventors and signed by the omitted inventor(s), identifying this application by the above Application Number and Filing Date, is required.
8. ☐ The application was filed in a language other than English. Applicant must file a verified English translation of the application and a fee of \$_____ under 37 CFR 1.17(k), unless this fee has already been paid.
9. ☐ A \$_____ processing fee is required for returned checks. (37 CFR 1.21(m)).
10. ☐ Your filing receipt was mailed in error because check was returned without payment.
11. ☐ The application does not comply with the Sequence Rules. See attached Notice to Comply with Sequence Rules 37 CFR 1.821-1.825.

11. ☐ Other 08/09/94 08243342

16-1150 130 105 130.0000

Direct the response and any questions about this notice to _____, Application Processing Division, Special Processing and Correspondence Branch (703) 308-1202.

A copy of this notice MUST be returned with the response.